Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

“The genes identified in this study fall into several categories, linked with much studied mechanisms such as metabolism within the cell, membrane drug pumps, and DNA repair, but also with apoptosis, suggesting that the general susceptibility of the cell to undergo this process may be an important determinant of tumor chemosensitivity, outweighing more specific mechanisms.”

Posted via web from sally church’s posterous

One Response to “Gene Assay To Help To Predict Lung Cancer Treatment Resistance”

  1. Pharma Ed

    Does this mean that chemotherapy treatments are going to be more effective? Could this research to the resistance of such drugs eliminate the countless side effects that patients suffer? If this is the case then I regard it as a major breakthrough.

Comments are closed.

error: Content is protected !!